Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Roth Capital
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price target […]
More Stories
Banc of California (BANC) Set to Announce Quarterly Earnings on Tuesday
Banc of California (NYSE:BANC – Get Free Report) will be releasing its earnings data before the market opens on Tuesday,...
Verisk Analytics (NASDAQ:VRSK) PT Raised to $300.00
Verisk Analytics (NASDAQ:VRSK – Free Report) had its target price boosted by Royal Bank of Canada from $268.00 to $300.00...
A.P. Møller – Mærsk A/S (OTCMKTS:AMKBY) Cut to Neutral at UBS Group
UBS Group cut shares of A.P. Møller – Mærsk A/S (OTCMKTS:AMKBY – Free Report) from a buy rating to a...
Alcoa (NYSE:AA) Upgraded to Buy at B. Riley
B. Riley upgraded shares of Alcoa (NYSE:AA – Free Report) from a neutral rating to a buy rating in a...
Woodside Energy Group Ltd (NYSE:WDS) Receives Consensus Rating of “Hold” from Analysts
Shares of Woodside Energy Group Ltd (NYSE:WDS – Get Free Report) have earned an average recommendation of “Hold” from the...
Cineplex (TSE:CGX) Price Target Raised to C$12.00 at Canaccord Genuity Group
Cineplex (TSE:CGX – Free Report) had its price objective raised by Canaccord Genuity Group from C$11.50 to C$12.00 in a...